Dos and Don’ts for High-Risk Elderly Patients With AF

Slides:

Advertisements

Similar presentations

Addressing the Challenges in Primary and Secondary Stroke Prevention

Advertisements

Which NVAF patients are candidates for TSOACs?

Covering the Bases in Cardioversion

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

NOACs for Cancer-Associated Thrombosis:

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

The ABCs of AF.

Access to NOAC Therapy:

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

A New Era for NOACs:.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Unmet Needs in the Secondary Prevention in ACS

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Up to Date on Which NOAC for Which Patient

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Through Thick and Thin.

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

REVERSAL AGENTS FOR NOACS: Do WE NEED THEM in THE EP LAB?

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

The Essentials for Secondary Stroke Prevention

New Oral Anticoagulants and VTE Management

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Efficacy and Safety of Edoxaban in Patients With AF and HF

AF and PCI in Practice.

Access to NOAC Therapy:

Antithrombotic Protection in CAD and HF

Adherence in SPAF: Measures to Improve Care

What Anticoagulant Registries Are Revealing

A Better Solution For Cancer Patients With VTE?

Which NVAF patients are candidates for NOACs?

Reversal Strategies for VKA: Truths and Misconceptions

Oral Anticoagulation in AF

Practical Considerations to Extend Treatment for VTE

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Identifying High-Risk AF Patients

CAD/PAD in Primary Care

What You Didn't Know About AF and Renal Dysfunction

Cancer-Associated Thrombosis

CAD and HF Often Coexist

A Case Challenge.

New European Anticoagulant Approvals Will They Affect Practical Guidance?

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Antithrombotics in Arterial Disease: Focus on Coronary Disease

The ABCs of AF.

Disease Burden of VTE Phases of VTE Treatment.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

5 Good Minutes on Atrial Fibrillation-related Stroke

NOACs and Reversal Agents

Antiarrhythmic Drugs in AF

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Presentation transcript:

Dos and Don’ts for High-Risk Elderly Patients With AF

Why Anticoagulate?

Anticoagulate Even in High-Risk Patients ?

Efficacy and Safety of NOACs vs Warfarin in NVAF by Age

Efficacy and Safety of Edoxaban vs Warfarin by Age in ENGAGE AF-TIMI 48

Efficacy and Safety of NOACs vs Warfarin in the ≥75 Age Group

Case Study

Case Study (cont)

Case Study: Delayed Cardioversion

Case Study: GI Bleed

Case Study: NOAC Switch

Case Study: Planned Cardioversion

Recommendations for Elderly Patients With AF

Prespecified CrCl Subgroups in ENGAGE AF-TIMI 48

Bleeding With Edoxaban and Warfarin by Concomitant Antiplatelet Use

Factors to Consider in High-Risk Patients With AF

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)